Cancer Vaccines

Dendritic/Cancer Cell Fusion Technology Licensed

Published in Cancer Weekly, March 21st, 2000

Genzyme Molecular Oncology, Framingham, Massachusetts, announced that it has exclusively licensed dendritic/cancer cell fusion technology for all therapeutic uses from Dana-Farber Cancer Institute.

This cancer vaccine technology was developed by Donald Kufe, MD, professor of medicine, and Jianlin Gong, MD, instructor of medicine, both at the Dana-Farber Cancer Institute and Harvard Medical School.

In March 2000, data from a German clinical study of a cancer vaccine to treat metastatic renal cancer (kidney cancer) based on Kufe's and Gong's concept of dendritic/cancer cell fusion were published in Nature Medicine (2000;6(3):332-336). The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-03-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry